FDA Fast Track Designation for BH-30643 for the Treatment of Advanced EGFR C797S-positive NSCLC August 25, 2026
Zipalertinib + Chemo Meet Primary PFS Endpoint in Planned Interim Analysis of Ph 3 REZILIENT3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC August 20, 2026
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HER2-mutant NSCLC in DESTINY-Lung04 Ph 3 trial August 20, 2026
IDMC recommends discontinuing the eVOLVE-Lung02 Ph 3 trial of volrustomig + chemo in 1L metastatic NSCLC with PD-L1 <50% August 20, 2026
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced non squamous NSCLC After Four Years of Follow-Up August 20, 2026
ORPATHYS + TAGRISSO Demonstrated Statistically Significant PFS/OS Improvements in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO August 20, 2026
Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026
Supplemental Application accepted for Toripalimab + Chemo as Perioperative Treatment for Resectable Stage II-III NSCLC July 28, 2026
Interim Safety Data in Ph 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients Reported July 22, 2026
Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint July 22, 2026
Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial July 15, 2026
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical July 15, 2026
Results from ELEVATE study of postoperative adjuvant ensartinib in stage IB–IIIB (T3N2M0) ALK-positive NSCLC published in NEJM July 15, 2026
Clinical results of Ph 1b/2 trial of ifebemtinib + garsorasib in 1L KRASG12C-mutant NSCLC published in The Lancet Respiratory Medicine July 15, 2026
Global Data for Pumitamig Shows Encouraging Efficacy in NSCLC Patients in ROSETTA Lung-02 Trial July 15, 2026
